The ERS living guideline document regarding the management of hospitalised adults with COVID-19 has been updated and republished.
The original guideline addressed 11 PICO questions related to the management of hospitalised adults with COVID-19. For the latest version of the guideline, no update was made to five questions, relating to corticosteroids, hydroxychloroquine, lopinavir-ritonavir, remdesivir and interferon-β. New evidence was considered for the remaining six questions, related to anticoagulation, continuous positive airway pressure therapy/high flow nasal oxygen, IL-6 receptor antagonist monoclonal antibodies, azithromycin, azithromycin and hydroxychloroquine combination treatment, and colchicine. Four new PICO questions were added to the guideline update, considering the evidence for treatment with convalescent plasma, specific anti-SARS-CoV-2 monoclonal antibodies, IL-1 receptor antagonist monoclonal antibodies, and JAK inhibitors. A summary of the recommendations can be found in table 1.
Further detail regarding this update to the living guideline is provided in the editorial published in this issue of the European Respiratory Journal [1].
- Copyright ©ERS 2022.